NEUROLOGICAL BIOMARKERS MARKET ANALYSIS

Neurological Biomarkers Market, By Biomarker Type (Artificial Tears, Imaging Biomarkers, Metabolomics Biomarkers, Proteomic Biomarkers, Genomics Biomarkers), By Application (Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, Autism Spectrum Disorders, Others), By End User (Hospital Laboratories, Clinical Diagnostic Centers, Research Organizations, Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

In October 2023, C2N Diagnostics, a molecular diagnostic, introduced an advanced fluid biomarker targeting neurofibrillary "Tau" tangle pathology in Alzheimer's Disease, offering researchers a crucial tool for monitoring disease progression by detecting Tau protein abnormalities. This breakthrough test marks significant progress in understanding and tracking Alzheimer's disease.
In July 2023, Quanterix Corporation, a life sciences company, launched LucentAD, a blood test utilizing biomarkers to aid in diagnosing Alzheimer’s disease in individuals
In November 2021, Eisai Co. Ltd, a Japan-based pharmaceutical company, and Biogen Inc., a global biotechnology company, revealed plans to present findings on the examination of plasma-based biomarkers in the Phase 3 AHEAD 3-45 trial of lecanemab (BAN2401), an experimental anti-amyloid beta (Aβ) protofibril antibody for Alzheimer's disease.
In October 2021, Diadem, a web hosting service provider, announced the release of clinical data demonstrating that its AlzoSure biomarker test can forecast the advancement of Alzheimer's disease several years before symptoms manifest.